Quitting Matters Human Immunodeficiency Virus Hybrid Trial
United States314 participantsStarted 2025-08-18
Plain-language summary
The purpose of this study is to compare the advantages and disadvantages of two approaches for quitting smoking among people living with HIV (PWH). Participants will complete a 24- week (\~6-month) study where the Participants will be assigned to one of two smartphone apps to help with quitting smoking. Regardless of the group participants are assigned to, they will also receive a combination of nicotine replacement therapy (patches and gums) that have been shown to help people quit smoking. The main questions this study aims to answer are:
Participants will complete 5 video call visits over about 6 months. Participants will install their assigned smoking cessation app onto their phone and will be asked to use the app for the duration of the study along with their provided Nicotine Replacement Therapy (NRT) products. During the study visits, participants will meet with study staff to complete questionnaires and interviews. Participants may be asked to provide breath and saliva samples to measure the level of carbon monoxide and nicotine.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Self-reported daily cigarette smoking over the past 30 days
✓. Self-reported HIV status
✓. Age 18 or older
✓. Desire to quit smoking
✓. Willing and medically eligible to use NRT
✓. Currently receiving HIV care
✓. Currently owning an Android or iOS smartphone
Exclusion criteria
✕. Current acute psychotic episode or unsafe to participate in the study
✕. Pregnant or intending to become pregnant in the next 6 months
✕. Currently receiving any pharmacological and/or behavioral intervention or counseling for smoking cessation
✕. Any medical condition or medication that could compromise subject safety, as determined by the PIs and/or study physician
What they're measuring
1
Biochemically verified 7-day point prevalence abstinence at 6, 12, 18, and 24-weeks